A detailed history of Diadema Partners LP transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 60,748 shares of TGTX stock, worth $1.88 Million. This represents 0.56% of its overall portfolio holdings.

Number of Shares
60,748
Previous 371,448 83.65%
Holding current value
$1.88 Million
Previous $13.4 Billion 83.58%
% of portfolio
0.56%
Previous 4.07%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$26.39 - $39.19 $8.2 Million - $12.2 Million
-310,700 Reduced 83.65%
60,748 $2.19 Billion
Q2 2025

Aug 14, 2025

BUY
$33.37 - $45.51 $5.46 Million - $7.44 Million
163,565 Added 78.68%
371,448 $13.4 Billion
Q1 2025

May 15, 2025

BUY
$27.67 - $42.99 $4.43 Million - $6.88 Million
160,078 Added 334.86%
207,883 $8.2 Billion
Q4 2024

Feb 14, 2025

BUY
$21.31 - $35.09 $1.02 Million - $1.68 Million
47,805 New
47,805 $1.44 Billion

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.5B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Diadema Partners LP Portfolio

Follow Diadema Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Diadema Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Diadema Partners LP with notifications on news.